GLPwatch
Achieving Over 30% Body Weight Loss With Semaglutide in a Patient: A Case Report.
Cureus · 2025
Last updated 2026-08-28| Journal | Cureus, 2025 |
|---|---|
| Citations | 0 |
| Molecules | semaglutide |
Abstract
A 69-year-old female with morbid obesity (BMI: 47) and hypertension achieved significant weight loss following treatment with semaglutide. Starting at 241 lb, she lost 90 lb (over 30% of her body weight) over 65 weeks without side effects. This weight loss exceeded the average reduction reported in previous studies. Additionally, her hypertension resolved, and her glucose levels normalized, illustrating the multifaceted benefits of semaglutide in weight management.
Verbatim abstract via PubMed 40125230 ↗
Related research
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
- Once-Weekly Semaglutide in Adults with Overweight or Obesity.
- Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
- A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
- Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
- Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.
- Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity.